Scopus Asset Management’s Colgate-Palmolive CL Stock Holding History

Scopus Asset Management’s Portfolio CL Stock Details CL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-200,000	Closed	-$14.1M	–	213
2022 Q3	$14.1M	Buy	+200,000	New	+$15.7M	0.52%	67

Other funds holding CL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Amundi Paris, France $367B AUM 31.23% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Scopus Asset Management's CL Position: Q4 2023 in Review

Scopus Asset Management sold out of Colgate-Palmolive (CL) in Q4 2023, closing a stake of 537,500 shares — an estimated $38.2M sold.

Scopus Asset Management first reported a position in CL in Q1 2017 and held it in 8 quarters. The position peaked at $69.9M in Q4 2022. 1,741 funds tracked by Wall St. Rank hold CL as of Q4 2023.

Scopus Asset Management reported no remaining Colgate-Palmolive position as of Q4 2023 after selling out during the quarter.
Scopus Asset Management sold 537,500 Colgate-Palmolive shares in Q4 2023, an estimated $38.2M.
Scopus Asset Management first reported a position in Colgate-Palmolive in Q1 2017 and held it in 8 quarters.
Scopus Asset Management's Colgate-Palmolive position peaked at $69.9M in Q4 2022.
1,741 funds tracked by Wall St. Rank held Colgate-Palmolive as of Q4 2023.

Based on Scopus Asset Management's 13F filing for Q4 2023, filed 14 Feb 2024.